



FOR IMMEDIATE RELEASE

Biolux Research Announces European Launch of the OsseoPulse™ Bone Regeneration System.

VANCOUVER, B.C., CANADA – Mar. 18, 2009 – Biolux Research Ltd. is pleased to announce today that it will be launching the OsseoPulse™ Bone Regeneration System at the 33rd International Dental Show from Mar. 24 – 29. <http://english.ids-cologne.de/> IDS 2009 in Cologne, Germany is the world's leading trade show and sector meeting place for decision-makers from dental practices, dental labs, the specialist dental trade, the dental industry and from research and development. More than 100,000 visitors gather information on new products and innovations from some 1,750 exhibitors from 55 countries.

Launch of the OsseoPulse™ in Europe builds on recent milestones of achieving both ISO 13485 certification and CE Mark regulatory approval for the product. The CE Mark allows Biolux to market the device directly to the 27 countries within the European Union plus the additional 4 countries that recognize the CE Mark. The dental implant market in Europe represents approximately 40% of the worldwide implant market, and is thus a significant market for Biolux and the OsseoPulse™.

“We are very excited to be launching the OsseoPulse™ to the world at the IDS,” states Kevin Strange, President and CEO of Biolux. “The IDS is the world's premier dentistry event, and we look forward to showing our product, spending time with existing distributors and research collaborators, and meeting new ones. We anticipate that we can develop new distribution networks from the meeting, as well as initiate sales in Europe.”

About Biolux Research

Biolux Research Ltd. is a world leader in the development of light activated bone regeneration systems for dentistry. Biolux focuses on product development, clinical and basic research, and its proprietary, patent-pending OsseoPulse™ Bone Regeneration System is premised on a vision to transform the practice of implantology and oral surgery in dentistry by accelerating implant integration and bone regeneration in a safe, effective and non-invasive approach. www.bioluxresearch.com

For More Information:

Kevin Strange
President & CEO
Biolux Research Ltd.
+1 (250) 686-1120
k.strange@bioluxresearch.com